Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check23 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check52 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has been updated to include specific drug names, such as Fludarabine and Cyclophosphamide, and a new version revision number. Additionally, the study now specifies that it has one location.SummaryDifference44%
- Check73 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added indicating March 7, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.2%
Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.